Wide Ranks

ATNM

Actinium Pharmaceuticals, Inc.

1.44

Top Statistics
Market Cap 44 M Forward PE -2.19 Revenue Growth 0.00 %
Current Ratio 8.95 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 0.7050 Enterprise / Revenue -404.73 Price To Sales Trailing12 Months 554.59
Profitability
Profit Margins 0.00 % Operating Margins -57665.44 %
Balance Sheet
Total Cash 86 M Total Cash Per Share 2.76 Total Debt 1 M
Total Debt To Equity 4.22 Current Ratio 8.95 Book Value Per Share 1.32
All Measures
Short Ratio 572.00 % Message Board Id finmb_7845787 Shares Short Prior Month 1 M
Return On Equity -0.8796 City New York Uuid 45c3a99a-9523-3f0f-ae76-8cfe4623774f
Previous Close 1.41 First Trade Date Epoch Utc 1 B Book Value 1.32
Beta 0.1460 Total Debt 1 M Volume 204694
Price To Book 1.09 Last Split Date 1 B Fifty Two Week Low 1.33
Total Cash Per Share 2.76 Total Revenue 81000 Shares Short Previous Month Date 1 B
Target Median Price 5.00 Audit Risk 9 Max Age 86400
Recommendation Mean 1.80 Sand P52 Week Change 0.3133 Operating Margins -57665.44 %
Target Mean Price 5.00 Net Income To Common -42623000 Ask 1.41
Short Percent Of Float 0.0466 Implied Shares Outstanding 31 M Last Fiscal Year End 1 B
Trailing Peg Ratio None Average Daily Volume10 Day 312430 Average Volume10days 312430
Total Cash 86 M Next Fiscal Year End 1 B Revenue Per Share 0.0030
Held Percent Insiders 0.0179 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Share Holder Rights Risk 6 Regular Market Previous Close 1.41
Target Low Price 2.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 1.72
Open 1.41 Free Cashflow -20060124 State NY
Dividend Yield 0.00 % Return On Assets -0.3091 Time Zone Short Name EST
Board Risk 9 Trailing Eps -1.39 Day Low 1.37
Address1 100 Park Avenue Shares Outstanding 31 M Compensation Risk 10
Price Hint 4 Target High Price 9.00 Website https://www.actiniumpharma.com
52 Week Change -0.6856 Average Volume 287900 Forward Eps -0.6900
Recommendation Key buy Compensation As Of Epoch Date 1 B Quick Ratio 884.40 %
Last Split Factor 1:30 Regular Market Day High 1.45 Is_sp_500 False
Profit Margins 0.00 % Debt To Equity 4.22 Fifty Two Week High 10.24
Day High 1.45 Shares Short 1 M Regular Market Open 1.41
Industry Key biotechnology Bid 1.41 Earnings Growth 0.00 %
Enterprise To Revenue -404.73 Revenue Growth 0.00 % Shares Percent Shares Out 0.0466
Operating Cashflow -33961000 Currency USD Time Zone Full Name America/New_York
Market Cap 44 M Is_nasdaq_100 False Zip 10017
Quote Type EQUITY Industry Biotechnology Long Name Actinium Pharmaceuticals, Inc.
Overall Risk 10 Regular Market Day Low 1.37 Held Percent Institutions 0.3011
Current Price 1.44 Address2 23rd Floor Enterprise To Ebitda 0.7050
Financial Currency USD Current Ratio 8.95 Gross Margins 100.00 %
Industry Disp Biotechnology Number Of Analyst Opinions 5 Country United States
Float Shares 30 M Two Hundred Day Average 5.38 Governance Epoch Date 1 B
Enterprise Value -32783280 Price To Sales Trailing12 Months 554.59 Forward PE -2.19
Regular Market Volume 204694 Ebitda -46485000 Exchange ASE
Go to Yahoo Finance Go to Seeking Alpha 
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies.

Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).

The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients.

In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies.

Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies.

Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications.

The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron.

The company is based in New York, New York.